Report Overview

The Global Huntingtons Disease drugs market size stood at USD 1.53 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Huntington's disease is an inherited disease that causes degeneration of nerve cells in the central nervous system (CNS). The disease has a broad impact on functional abilities of the human and usually results in movement and thinking disabilities. Most people with Huntington's disease develop signs and symptoms in their age of 30 to 40. When disease begins before age 20, the condition is known as juvenile Huntington's disease. Both men and women are susceptible to this disease. Studies show that one in every 10,000 people in America has HD and more than 250,000 people are at risk of inheriting the disease from a parent.

Both men and women are susceptible to this disease. Studies show that one in every 10,000 people in America has HD and more than 250,000 people are at risk of inheriting the disease from a parent.



Market Drivers

The pipeline for Huntington's disease is expected to witness rapid developments in the coming years as disease-modifying drugs transform the market landscape. Improved disease understanding has led to significant progress in the development of therapeutic approaches aimed at modifying specific changes linked to the causative mutation.

The potential role of RNA antisense technology and stem cell therapy are under active clinical investigation. Wave Life Sciences and Ionis Pharma's antisense oligonucleotides aim to target underlying disease cause and are expected to contribute significantly to market growth.